Trial · NCT07885176
Deep Repetitive Transcranial Magnetic Stimulation in the Treatment of Tinnitus
NCT07885176, Not applicable, Recruiting, University of Regensburg
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Deep Repetitive Transcranial Magnetic Stimulation in the Treatment of Tinnitus. Trials, record NCT07885176. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885176
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Deep Repetitive Transcranial Magnetic Stimulation in the Treatment of Tinnitus
- NCT number
- NCT07885176
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- University of Regensburg
- Conditions
- Tinnitus, Tinnitus, Bilateral
- Interventions
- DeepTms
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in Tinnitus Burden | 12 weeks: from enrollment to the end of treatment after two weeks, plus Follow Up after 10 weeks | Changes in Tinnitus Burden Measured Using the Tinnitus Handicap Inventory (THI) from Baseline to the End of Treatment, Including Group Comparisons. The THI consists of 25 items designed to evaluate the perceived impact of tinnitus on an individual's daily life. Each item provides three response options: 'No', 'Sometimes' and 'Yes', which are scored as 0, 2 and 4 points respectively. The total THI score is obtained by summing the scores of all items, resulting in a score that ranges from 0 to 100, with higher scores indicating greater perceived handicap due to tinnitus. |
| Secondary | Tinnitus Functional Index (TFI) | 12 weeks: from enrollment to end of treatment after 2 weeks, plus Follow Up after 10 weeks | Changes in TFI: The TFI measures the functional impact of tinnitus and consists of 25 items. It includes 8 subscales: cognitive interference, auditory perceptual difficulties, intrusiveness, sleep disturbances, disturbances of relaxation, quality of life impairment, emotional distress, and reduced sense of control. The total score ranges from 0 and 100. A lower score indicates greater perceived distress due to tinnitus. |
| Secondary | Tinnitus loudness | 12 weeks: from enrollment to end of treatment after 2 weeks, plus Follow Up after 10 weeks | short-term changes in tinnitus loudness, ranging from 0% to 200% (0%=no tinnitus perception, 50% = half of the usually perceived tinnitus loudness, 100% usually perceived tinnitus loudness, 200%=twice as loud as usually perceived tinnitus loudness |
| Secondary | Clinical Global Inventory - Improvement Scale | end of treatment after two weeks, plus Follow Up after 10 weeks | Within 1 question, patients are asked to rate the overall improvement of their tinnitus complaints compared to before the treatment has started on a 7-point Likert scale (1-"very much better," 2-"much better," 3-"minimally better," 4-"no change," 5-"minimally worse," 6-"much worse," 7-"very much worse"). |
| Secondary | Mini-Tinnitus Questionnaire (Mini-TQ) | 12 weeks: from enrollment to end of treatment after 2 weeks, plus Follow Up after 10 weeks | The Mini-TQ is a validated, 12-item patient-reported outcome measure designed to assess tinnitus-related psychological distress and its impact on daily life. Each item is scored on a 3-point scale: true (2 points), partly true (1 point), or not true (0 points), yielding a total score of 0-24, with higher scores indicating greater tinnitus-related distress. |
| Secondary | Major Depression Inventory (MDI) | 12 weeks: from enrollment to end of treatment after 2 weeks, plus Follow Up after 10 weeks | The MDI is a validated 10-item self-report questionnaire assessing depressive symptoms. Items are rated from 0 (at no time) to 5 (all the time). For items 8 and 10, the higher sub-item score is used. The total score ranges from 0-50, with higher scores indicating greater depressive symptom severity. |
| Secondary | Tinnitus Analogue Scales | 12 weeks: from enrollment to end of treatment after 2 weeks, plus Follow Up after 10 weeks | Participants rate the loudness of their tinnitus (0-not at all loud; 10-extremely loud), the tinnitus-induced discomfort (0-no discomfort; 10-severe discomfort), annoyance (0-not at all annoying; 10-extremely annoying), unpleasantness (0-not at all unpleasant; 10-extremely unpleasant) as well as the possibility to ignore their tinnitus (0-very easy to ignore; 10-impossible to ignore) on a Visual Analog Scale (VAS). |
| Secondary | World Health Organization-Quality of Life instrument (WHOQOL-BREF) | 12 weeks: from enrollment to end of treatment after 2 weeks, plus Follow Up after 10 weeks | A 26-item validated, self-report questionnaire assessing quality of life across four domains: physical health (items 3, 4, 10, 15-18), psychological health (items 5-7, 11, 19, 26), social relationships (items 20-22), and environment (items 8, 9, 12-14, 23-25). Items 1 and 2 assess overall quality of life and general health, respectively. Scoring: Items are rated on a 5-point scale (1-5). Domain scores are transformed to a 4-20 or 0-100 scale, with higher scores indicating better quality of life. Items 3, 4, and 26 are reverse-scored. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24685051 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07885176
GET https://conductscience.org/api/trials/v1/NCT07885176/registered